Glofitamab Treatment for DLBCL Shows Cost Savings Over Epcoritamab in US Healthcare
An economic model reveals glofitamab offers DLBCL patient cost savings versus epcoritamab, despite higher adverse event and treatment administration costs.
Browsing Tag
health care costs
Cancer Drug Launch Prices Skyrocket Beyond Inflation
Medicare Part D anticancer drugs' launch prices have surged since 2012, even outpacing inflation rates, despite the…
Sura Exits Colombia’s Health System Amid Government Takeover
TL/DR -
Colombian insurance firm Sura is withdrawing from the national health system, citing inadequate funding…
State Medicaid Targets Deceased’s Estates for Health Cost Recovery
TL/DR -
The US government requires states to recover money from the assets of deceased Medicaid patients who relied on the taxpayer-funded health insurance. However, a Democratic lawmaker recently proposed disbanding this program, arguing that it collects only around 1% of the more than $150 billion Medicaid spends annually on long-term care. The…
Etiqa Unveils Essential Critical Secure Plan with Mental Health Aid | Singapore…
TL/DR -
The content presents a form for users to select their state, input their zip code, and select their…
Facing the True Health Care Crisis: Overuse of ‘Crisis’ Label
TL/DR -
The term "health care crisis" is routinely used, but the overuse of the term may be detracting from the…